全文获取类型
收费全文 | 12406篇 |
免费 | 604篇 |
国内免费 | 100篇 |
专业分类
耳鼻咽喉 | 62篇 |
儿科学 | 157篇 |
妇产科学 | 192篇 |
基础医学 | 1509篇 |
口腔科学 | 146篇 |
临床医学 | 760篇 |
内科学 | 3648篇 |
皮肤病学 | 223篇 |
神经病学 | 808篇 |
特种医学 | 592篇 |
外科学 | 2337篇 |
综合类 | 81篇 |
预防医学 | 218篇 |
眼科学 | 129篇 |
药学 | 816篇 |
4篇 | |
中国医学 | 42篇 |
肿瘤学 | 1386篇 |
出版年
2024年 | 26篇 |
2023年 | 107篇 |
2022年 | 189篇 |
2021年 | 333篇 |
2020年 | 162篇 |
2019年 | 210篇 |
2018年 | 273篇 |
2017年 | 232篇 |
2016年 | 297篇 |
2015年 | 325篇 |
2014年 | 390篇 |
2013年 | 426篇 |
2012年 | 760篇 |
2011年 | 871篇 |
2010年 | 452篇 |
2009年 | 437篇 |
2008年 | 732篇 |
2007年 | 915篇 |
2006年 | 848篇 |
2005年 | 846篇 |
2004年 | 838篇 |
2003年 | 862篇 |
2002年 | 796篇 |
2001年 | 145篇 |
2000年 | 94篇 |
1999年 | 158篇 |
1998年 | 205篇 |
1997年 | 177篇 |
1996年 | 139篇 |
1995年 | 141篇 |
1994年 | 95篇 |
1993年 | 118篇 |
1992年 | 76篇 |
1991年 | 47篇 |
1990年 | 58篇 |
1989年 | 41篇 |
1988年 | 43篇 |
1987年 | 34篇 |
1986年 | 27篇 |
1985年 | 14篇 |
1984年 | 18篇 |
1983年 | 21篇 |
1982年 | 18篇 |
1981年 | 11篇 |
1980年 | 18篇 |
1979年 | 8篇 |
1978年 | 9篇 |
1977年 | 8篇 |
1975年 | 7篇 |
1974年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
91.
92.
93.
Daisuke Tamanoi Koichi Saruwatari Kosuke Imamura Ryo Sato Takuya Jodai Shohei Hamada Yusuke Tomita Sho Saeki Shikiko Ueno Yuji Yonemura Hidenori Ichiyasu Takuro Sakagami 《Internal medicine (Tokyo, Japan)》2022,61(11):1731
The effect of radiotherapy during immunotherapy on immune-related adverse events (irAEs) is not fully understood. We herein report a 74-year-old woman diagnosed with lung adenocarcinoma with programmed death ligand 1 expression ≥50% and treated with pembrolizumab. She developed fatal immune thrombocytopenia associated with pembrolizumab immediately following radiotherapy. A flow cytometry analysis of peripheral blood detected an increased expression of programmed death-1 (PD-1) and Ki-67 in CD4+ and CD8+ T cells after radiotherapy, compared with pre-irradiation measurements. This case suggests that radiotherapy may evoke irAEs during treatment with anti-PD-1 antibodies, which physicians should consider when using radiotherapy in patients treated with these drugs. 相似文献
94.
Kensei Yamaguchi Keiko Minashi Daisuke Sakai Tomohiro Nishina Yasushi Omuro Masahiro Tsuda Shiroh Iwagami Hisato Kawakami Taito Esaki Naotoshi Sugimoto Takashi Oshima Ken Kato Kenji Amagai Hisashi Hosaka Keigo Komine Hisateru Yasui Yuji Negoro Kenji Ishido Takahiro Tsushima Shirong Han Shinichi Shiratori Tomoko Takami Kohei Shitara 《Cancer science》2022,113(8):2814
The KEYNOTE‐659 study evaluated the efficacy and safety of first‐line pembrolizumab plus S‐1 and oxaliplatin (SOX) (cohort 1) or S‐1 and cisplatin (SP) (cohort 2) for advanced gastric/gastroesophageal junction (G/GEJ) cancer in Japan. Herein, we update the results of cohort 1 and describe the results of cohort 2. This open‐label phase IIb study enrolled patients with advanced programmed death‐ligand 1 (PD‐L1)‐positive (combined positive score ≥ 1) human epidermal growth factor receptor 2 (HER2)‐negative G/GEJ adenocarcinoma. The primary end‐point was the objective response rate (ORR). Other end‐points were duration of response (DOR), disease control rate (DCR), progression‐free survival (PFS), overall survival (OS), and safety. One hundred patients were enrolled. In cohorts 1 and 2, median follow‐up time was 16.9 and 17.1 months; ORR (central review), 72.2% and 80.4%; DOR, 10.6 and 9.5 months; DCR (central review), 96.3% and 97.8%; median PFS (central review), 9.4 and 8.3 months; and median OS, 16.9 and 17.1 months, respectively. Treatment‐related adverse events (TRAEs) occurred in all patients, including peripheral sensory neuropathy (94.4%, cohort 1), decreased neutrophil count (82.6%, cohort 2), nausea (59.3% and 60.9% in cohorts 1 and 2), and decreased appetite (61.1% and 60.9% in cohorts 1 and 2). Grade 3 or higher TRAEs were reported by 59.3% (cohort 1) and 78.3% (cohort 2), including decreased platelet count (14.8%, cohort 1) and decreased neutrophil count (52.2%, cohort 2). Pembrolizumab in combination with SOX or SP showed favorable efficacy and safety in patients with PD‐L1‐positive, HER2‐negative G/GEJ adenocarcinoma. 相似文献
95.
Choi J Koh E Matsui F Sugimoto K Suzuki H Maeda Y Yoshida A Namiki M 《Fertility and sterility》2008,89(5):1177-1182
96.
97.
98.
Matsuura T Takehara Y Kaijima H Teramoto S Kato O 《Journal of assisted reproduction and genetics》2008,25(4):163-167
Purpose Although many reports support stimulated in vitro fertilization, several patients do not respond to it well. Furthermore,
stimulated treatment could be associated with reduced ovarian response. We describe three successful cases involving patients
of advanced age from whom dominant follicles were retrieved during the natural cycle.
Materials and methods All patients had failed to bear children through stimulated in vitro fertilization. In case 1, a follicle was retrieved after
a gonadotropin-releasing hormone agonist was used to induce luteinizing hormone surge. In cases 2 and 3, pregnancy was achieved
via completely natural cycles.
Results One embryo was transferred every 16 cycles. Ongoing pregnancy—defined as pregnancy progressing beyond gestation week 9—was
established in three cycles. The patients successfully delivered and had uneventful neonatal courses.
Conclusion Mature oocyte retrieval followed by natural rather than stimulated in vitro fertilization might be a potential treatment for
patients of advanced age when stimulated in vitro fertilization has been repeatedly unsuccessful.
Capsule We describe three successful pregnancies and deliveries achieved via natural IVF cycles: the patients were older than 37 years
with repeated failures by stimulated IVF. 相似文献
99.
Naoyuki Kanayama Fumiaki Isohashi Yasuo Yoshioka Sungjae Baek Masashi Chatani Tadayuki Kotsuma Eiichi Tanaka Ken Yoshida Yuji Seo Osamu Suzuki Seiji Mabuchi Yasuhiko Shiki Keiji Tatsumi Tadashi Kimura Teruki Teshima Kazuhiko Ogawa 《Journal of radiation research》2015,56(2):346-353
The purpose of this study was to determine the outcomes and optimal practice patterns of definitive radiotherapy for primary vaginal cancer. Between 1993 and 2012, 49 patients were treated with definitive radiotherapy for primary vaginal cancer in three hospitals. Of these, 15 patients (31%) had clinically positive regional lymph node metastasis. A total of 34 patients (70%) received external beam radiotherapy with high-dose-rate brachytherapy (interstitial or intracavitary), and 8 (16%) (with small superficial Stage I tumors) were treated with local radiotherapy. The median follow-up was 33 months (range: 1–169 months). The 3-year overall survival (OS), disease-free survival (DFS), and loco-regional control (LRC) rates were 83%, 59% and 71%, respectively. In multivariate analysis, the histological type (P = 0.044) was significant risk factors for LRC. In Federation of Gynecology and Obstetrics (FIGO) Stage I cases, 3 of 8 patients (38%) who did not undergo prophylactic lymph node irradiation had lymph node recurrence, compared with 2 of 12 patients (17%) who underwent prophylactic pelvic irradiation. For Stage III–IV tumors, the local recurrence rate was 50% and the lymph node recurrence rate was 40%. Patients with FIGO Stage I/II or clinical Stage N1 had a higher recurrence rate with treatment using a single modality compared with the recurrence rate using combined modalities. In conclusion, our treatment outcomes for vaginal cancer were acceptable, but external beam radiotherapy with brachytherapy (interstitial or intracavitary) was needed regardless of FIGO stage. Improvement of treatment outcomes in cases of FIGO Stage III or IV remains a significant challenge. 相似文献
100.
Hiroyuki Fujiwara Akihiro Shimoda Yoshiki Ishikawa Akiyo Taneichi Mai Ohashi Yoshifumi Takahashi Takahiro Koyanagi Hiroyuki Morisawa Suzuyo Takahashi Naoto Sato Shizuo Machida Yuji Takei Yasushi Saga Mitsuaki Suzuki 《Archives of Public Health》2015,73(1)